

CTI BIOPHARMA CORP  
Form 8-K/A  
April 29, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

Amendment No. 1

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2015

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

Washington  
(State or other jurisdiction)

001-12465 91-1533912  
(Commission (I.R.S. Employer

Edgar Filing: CTI BIOPHARMA CORP - Form 8-K/A

(State or other jurisdiction of incorporation or organization) (File Number) (Identification Number)

3101 Western Avenue, Suite 600

Seattle, Washington 98121

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

Not applicable

(Former name or former address, if changed since last report).

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

CTI BioPharma Corp. (the “Company”) filed a Current Report on March 23, 2015 reporting that the Company’s 2015 annual meeting of shareholders (the “Annual Meeting”) would take place on June 30, 2015. This Amendment No. 1 is being filed to report that the Annual Meeting has been rescheduled due to administrative and scheduling reasons.

The Company will announce the Annual Meeting’s new date, time and related deadlines after a final determination regarding those items has been made. The Company will subsequently file and mail proxy materials as required.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: April 29, 2015 By: /s/ Louis A. Bianco  
Louis A. Bianco  
Executive Vice President, Finance and  
Administration